NO326302B1 - Metode for a ekstrahere proteiner - Google Patents
Metode for a ekstrahere proteiner Download PDFInfo
- Publication number
- NO326302B1 NO326302B1 NO19992099A NO992099A NO326302B1 NO 326302 B1 NO326302 B1 NO 326302B1 NO 19992099 A NO19992099 A NO 19992099A NO 992099 A NO992099 A NO 992099A NO 326302 B1 NO326302 B1 NO 326302B1
- Authority
- NO
- Norway
- Prior art keywords
- sample
- extractant
- calprotectin
- samples
- protein
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 102
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 46
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 46
- 238000000605 extraction Methods 0.000 claims abstract description 42
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 28
- 239000000284 extract Substances 0.000 claims abstract description 17
- 239000002738 chelating agent Substances 0.000 claims abstract description 9
- 239000007788 liquid Substances 0.000 claims abstract description 9
- 239000011343 solid material Substances 0.000 claims abstract description 5
- 241000124008 Mammalia Species 0.000 claims abstract description 4
- 239000011344 liquid material Substances 0.000 claims abstract description 4
- 239000006185 dispersion Substances 0.000 claims abstract description 3
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims description 62
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 claims description 62
- 210000003608 fece Anatomy 0.000 claims description 33
- 239000003795 chemical substances by application Substances 0.000 claims description 25
- 239000012528 membrane Substances 0.000 claims description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 13
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 11
- 239000004202 carbamide Substances 0.000 claims description 11
- 102000001554 Hemoglobins Human genes 0.000 claims description 9
- 108010054147 Hemoglobins Proteins 0.000 claims description 9
- 238000005119 centrifugation Methods 0.000 claims description 5
- 229910021645 metal ion Inorganic materials 0.000 claims description 5
- 239000007983 Tris buffer Substances 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 238000000265 homogenisation Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 claims description 2
- 238000001839 endoscopy Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000002575 gastroscopy Methods 0.000 claims description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
- 230000008569 process Effects 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 47
- 238000012360 testing method Methods 0.000 description 21
- 239000006228 supernatant Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000011575 calcium Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000003715 calcium chelating agent Substances 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000011109 contamination Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 229940098773 bovine serum albumin Drugs 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 3
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012864 cross contamination Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000000368 destabilizing effect Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000751 protein extraction Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 230000000087 stabilizing effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PLKYJWLKIDFVHM-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;urea Chemical compound NC(N)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O PLKYJWLKIDFVHM-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- -1 ECTA Chemical compound 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000024558 digestive system cancer Diseases 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/795—Porphyrin- or corrin-ring-containing peptides
- G01N2333/805—Haemoglobins; Myoglobins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
- Y10S436/813—Cancer
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Extraction Or Liquid Replacement (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9622839A GB9622839D0 (en) | 1996-11-01 | 1996-11-01 | Process |
| GB9707148A GB9707148D0 (en) | 1997-04-08 | 1997-04-08 | Process |
| PCT/GB1997/003013 WO1998020355A1 (en) | 1996-11-01 | 1997-11-03 | Process for the extraction of proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO992099L NO992099L (no) | 1999-04-30 |
| NO992099D0 NO992099D0 (no) | 1999-04-30 |
| NO326302B1 true NO326302B1 (no) | 2008-11-03 |
Family
ID=26310325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19992099A NO326302B1 (no) | 1996-11-01 | 1999-04-30 | Metode for a ekstrahere proteiner |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6225072B1 (de) |
| EP (1) | EP0937259B1 (de) |
| JP (1) | JP4105768B2 (de) |
| AT (1) | ATE278964T1 (de) |
| AU (1) | AU4790597A (de) |
| CA (1) | CA2268926A1 (de) |
| DE (1) | DE69731103T2 (de) |
| DK (1) | DK0937259T3 (de) |
| ES (1) | ES2225956T3 (de) |
| NO (1) | NO326302B1 (de) |
| PT (1) | PT937259E (de) |
| WO (1) | WO1998020355A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0229747D0 (en) | 2002-12-20 | 2003-01-29 | Axis Shield Asa | Assay |
| JP5227418B2 (ja) * | 2007-11-20 | 2013-07-03 | エフ．ホフマン−ラ ロシュ アーゲー | マーカー組み合わせカルプロテクチンおよびヘモグロビン／ハプトグロビン複合体の使用による便試料からの結腸直腸癌の評価方法 |
| JP2012507723A (ja) * | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| EP2202320A1 (de) | 2008-12-24 | 2010-06-30 | Agendia B.V. | Verfahren und Mittel zur Typisierung einer Probe mit Kolorektalkrebszellen |
| WO2011062549A1 (en) | 2009-11-23 | 2011-05-26 | Johansson, Enar Bernt | Method used in a human or animal faeces sample processing system, and a sample processing system |
| NO336551B1 (no) | 2011-06-21 | 2015-09-28 | Magne Fagerhol | Forbedret ELISA for kalprotektin i fekalprøve eller gastrointestinaltraktsprøve |
| NO20110895A1 (no) | 2011-06-21 | 2012-12-24 | Magne Fagerhol | Kompetitive S100A9 immunoanalyser |
| WO2013132338A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Competitive immunoassay for calprotectin |
| WO2013132347A2 (en) | 2012-03-06 | 2013-09-12 | Calpro As | Improved elisa immunoassay for calprotectin |
| DK2947459T3 (en) | 2014-05-21 | 2017-10-23 | Bühlmann Laboratories Ag | Method for Determining a Protein |
| WO2017049035A1 (en) | 2015-09-17 | 2017-03-23 | Amgen Inc. | Prediction of clinical response to il23-antagonists using il23 pathway biomarkers |
| AU2016379157A1 (en) | 2015-12-22 | 2018-06-21 | Amgen Inc. | CCL20 as a predictor of clinical response to IL23-antagonists |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8318754D0 (en) | 1983-07-11 | 1983-08-10 | Fagerhol M K F | Human proteins anti-sera test kits |
| EP0281251A3 (de) * | 1987-02-04 | 1988-09-28 | International Immunoassay Laboratories, Inc. | Verfahren zur Zubereitung einer fäkalen Probenzusammensetzung für immunologische Nachprüfung |
| US5139934A (en) * | 1990-05-25 | 1992-08-18 | Becton, Dickinson And Company | Substrate composition and method for solid phase urease immunoassay |
| US5455160A (en) * | 1993-05-27 | 1995-10-03 | Fagerhol; Magne K. | Diagnostic test and kit for disease or disorders in the digestive system |
-
1997
- 1997-11-03 DK DK97910561T patent/DK0937259T3/da active
- 1997-11-03 DE DE69731103T patent/DE69731103T2/de not_active Expired - Lifetime
- 1997-11-03 PT PT97910561T patent/PT937259E/pt unknown
- 1997-11-03 JP JP52113898A patent/JP4105768B2/ja not_active Expired - Fee Related
- 1997-11-03 EP EP97910561A patent/EP0937259B1/de not_active Expired - Lifetime
- 1997-11-03 CA CA002268926A patent/CA2268926A1/en not_active Abandoned
- 1997-11-03 ES ES97910561T patent/ES2225956T3/es not_active Expired - Lifetime
- 1997-11-03 AT AT97910561T patent/ATE278964T1/de not_active IP Right Cessation
- 1997-11-03 AU AU47905/97A patent/AU4790597A/en not_active Abandoned
- 1997-11-03 WO PCT/GB1997/003013 patent/WO1998020355A1/en not_active Application Discontinuation
-
1999
- 1999-04-30 NO NO19992099A patent/NO326302B1/no not_active IP Right Cessation
- 1999-05-03 US US09/303,611 patent/US6225072B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| PT937259E (pt) | 2005-01-31 |
| NO992099L (no) | 1999-04-30 |
| ES2225956T3 (es) | 2005-03-16 |
| JP4105768B2 (ja) | 2008-06-25 |
| DE69731103T2 (de) | 2005-11-17 |
| WO1998020355A1 (en) | 1998-05-14 |
| JP2001503863A (ja) | 2001-03-21 |
| NO992099D0 (no) | 1999-04-30 |
| ATE278964T1 (de) | 2004-10-15 |
| DK0937259T3 (da) | 2005-01-31 |
| EP0937259A1 (de) | 1999-08-25 |
| US6225072B1 (en) | 2001-05-01 |
| EP0937259B1 (de) | 2004-10-06 |
| AU4790597A (en) | 1998-05-29 |
| DE69731103D1 (de) | 2004-11-11 |
| CA2268926A1 (en) | 1998-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Danko et al. | The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy | |
| Coe et al. | Uric acid saturation in calcium nephrolithiasis | |
| Savory et al. | A biuret method for determination of protein in normal urine | |
| Pollock et al. | Dysmorphism of urinary red blood cells—value in diagnosis | |
| NO326302B1 (no) | Metode for a ekstrahere proteiner | |
| DE60033380T2 (de) | Verfahren zur quantifizierung der zahl von leukozyten in einer blutprobe | |
| AU2015261919B2 (en) | Method for determination of a protein | |
| Grover et al. | Evidence for the presence of abnormal proteins in the urine of recurrent stone formers | |
| Porowski et al. | Correspondence between Ca 2+ and calciuria, citrate level and pH of urine in pediatric urolithiasis | |
| Ferraz et al. | Preservation of urine samples for metabolic evaluation of stone-forming patients | |
| DE69933707T2 (de) | Serum amyloid a als marker für entzündungsreaktion, milchqualität und die anwesenheit von kolostrum in milch | |
| Kelly et al. | Induced sputum: validity of fluid-phase IL-5 measurement | |
| Fan et al. | Examination of crystalluria in freshly voided urines of recurrent calcium stone formers and normal individuals using a new filter technique | |
| DE69635979T2 (de) | Verfahren zur bestimmung des hepatischen zustands eines lebertransplantationsempfängers. | |
| Erdener et al. | Urinary N‐acetyl‐β‐d‐glucosaminidase (NAG) in lupus nephritis and rheumatoid arthritis | |
| Georgopoulos et al. | Evaluation of asymptomatic microscopic haematuria—influence and clinical relevance of osmolality and pH on urinary erythrocyte morphology | |
| DE69736893T2 (de) | Oxydativer stoffwechsel in glatten muskelzellen: verfahren in beziehung dazu | |
| Harvey et al. | Fluorometric assay of protein in native human bile | |
| Janssen et al. | Immunochemical determination of human tear lysozyme (muramidase) in keratoconjunctivitis sicca | |
| US5039619A (en) | Method for detecting characteristic markers of disease in biological fluids | |
| Sleeman et al. | Analysis of urine from free-ranging mountain gorillas (Gorilla gorilla beringei) for normal physiologic values | |
| RU2680848C1 (ru) | Способ оценки характера аутоиммунной реакции организма человека на множественно модифицированные липопротеины низкой плотности в литическом тесте | |
| Kanauchi et al. | Diagnostic significance of urinary fibronectin in diabetic nephropathy | |
| EP0467973B1 (de) | Sublethaler biotest zur bestimmung der umweltqualität | |
| Horpácsy | Diagnostic Significance of Standardized Determination of Urinary Enzymes1 in the Practice of Human Kidney Transplantation and Renal Toxicology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |